Bio-Techne (TECH) has received a new Buy rating, initiated by Wells Fargo analyst, Brandon Couillard.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Couillard has given his Buy rating due to a combination of factors that highlight Bio-Techne’s strong market position and growth potential. The company is expected to deliver above-average organic revenue and earnings growth, driven by its unique portfolio and exposure to high-growth sectors such as GMP reagents and precision diagnostics. Despite recent stock declines, the current valuation presents an attractive entry point for investors, as the stock trades below its historical average.
Furthermore, Bio-Techne’s robust margin profile and potential for margin expansion through strategic acquisitions contribute to its appeal. The company’s balance sheet is strong, with the potential to be in a net cash position soon, allowing for strategic acquisitions and share repurchases. Additionally, concerns about U.S. government funding cuts are considered to be already factored into the stock price, minimizing downside risk. These elements collectively support the Buy rating, with a price target of $59.